Table 3 Drug resistance-related risk factors univariate analysis
分组 | Total cases | Resistant group | Sensitive group | P | ||
|---|---|---|---|---|---|---|
Cases | Rate(%) | Cases | Rate(%) | |||
FIGO Stages | ||||||
I | 19 | 1 | 2.94 | 18 | 31.03 | 0.01 |
II | 13 | 3 | 8.82 | 10 | 17.24 | |
III | 60 | 30 | 88.24 | 30 | 51.72 | |
IV | 0 | 0 | 0 | 0 | 0 | |
Differentiation | ||||||
High | 15 | 5 | 14.71 | 10 | 17.24 | 0.298 |
Moderate | 35 | 12 | 35.29 | 23 | 39.66 | |
Poorly | 42 | 17 | 50.00 | 25 | 43.10 | |
Histologic subtype | ||||||
Serous cystadenocarcinoma | 58 | 24 | 70.59 | 34 | 58.62 | 0.872 |
Mucinous cystadenocarcinoma | 8 | 4 | 11.76 | 4 | 6.90 | |
Endometrioid carcinoma | 4 | 1 | 2.94 | 3 | 5.17 | |
Clear cell carcinoma | 7 | 1 | 2.94 | 6 | 10.34 | |
Poorly differentiated adenocarcinoma | 15 | 4 | 11.76 | 11 | 18.87 | |